Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 04 Sep 2017
At a glance
- Drugs GSK 3390107A (Primary) ; RVSV-S-GP/VP40 vaccine (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Acronyms PREVAIL
- 17 Nov 2016 Planned number of patients changed from 28170 to 1500.
- 18 Aug 2016 Planned End Date changed from 1 Jun 2017 to 1 Jun 2020.
- 10 Aug 2016 Status changed from recruiting to active, no longer recruiting.